Arquivos do dia: Janeiro 28, 2022

Estudo randomizado | Imunoglobulina hiperimune não melhorou os desfechos de pacientes internados com COVID-19.

28 Jan, 2022 | 17:24h

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial – The Lancet

Comentários:

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19 – The Lancet

Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19 – NIH News Releases

---

Características clínicas e desfechos de pacientes com síndrome da angústia respiratória aguda associada à COVID-19 submetidos a transplante de pulmão.

28 Jan, 2022 | 17:23h

Clinical Characteristics and Outcomes of Patients With COVID-19–Associated Acute Respiratory Distress Syndrome Who Underwent Lung Transplant – JAMA

Conteúdos relacionados: Cases of lung transplantation for Covid-19–related respiratory failure in the US were associated with a three-month survival of 95.6%.

---

Perspectiva | Em que ponto estamos com a Ômicron? Dados, cálculos, padrões e saída.

28 Jan, 2022 | 17:21h

Where do we stand with Omicron? – by Dr. Eric Topol

 

Comentário no Twitter

Where do we stand with Omicron?
I've summarized the new data, math, patterns, and potential exit ramphttps://t.co/SyCmCzkBQX @SubstackInc

— Eric Topol (@EricTopol) January 22, 2022

 

---

Estudo randomizado | Vacinação heteróloga de AD5-nCOV com CoronaVac vs. vacinação homóloga com CoronaVac.

28 Jan, 2022 | 17:20h

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial – Nature Medicine

Conteúdos relacionados:

RCT: Heterologous (Pfizer, J&J, or AstraZeneca) vs. homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil.

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination – Nature Medicine

WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.

---

Após a Ômicron, alguns cientistas preveem “um período de calmaria”.

28 Jan, 2022 | 17:19h

After Omicron, some scientists foresee ‘a period of quiet’ – Science

---

Perspectiva | A variante Ômicron tornará imune a maioria de nós?

28 Jan, 2022 | 17:18h

Will Omicron Leave Most of Us Immune? – The Atlantic

---

Uma segunda versão da variante Ômicron está se disseminando. Este é o motivo de os cientistas estarem alertas.

28 Jan, 2022 | 17:16h

A second version of omicron is spreading. Here’s why scientists are on alert – NPR

Ver também: Scientists Watch, Worry About New ‘Stealth’ Version of Omicron Variant – HealthDay

---

Eles construíram uma abordagem mais inteligente para os estudos clínicos de Covid. Agora, eles querem fazer o mesmo para outras doenças.

28 Jan, 2022 | 17:15h

They built a smarter approach to Covid clinical trials. Now they want to do the same for other diseases – STAT

---

O lado positivo da moeda: a pandemia de SARS-CoV-2 nos ensinou sobre o quanto a telemedicina é útil como procedimento padrão de cuidado na vida real.

28 Jan, 2022 | 17:14h

The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life – Clinical Rheumatology

---

Casualidades da COVID: insulina e diálise – “Como a pandemia tem sido uma ameaça à vida de pessoas com diabetes e doença renal crônica.”

28 Jan, 2022 | 17:13h

Casualties of COVID: Insulin and Dialysis - Think Global Health

---